+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

HP (High Potency) APIs Global Market Report 2022: By Type, By Synthesis, By Therapeutic

  • PDF Icon

    Report

  • 400 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5553739
HP (High Potency) APIs Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global high potency APIs.



This report focuses on the HP (High Potency) API market which is experiencing strong growth. The report gives a guide to the HP (High Potency) APIs global market report which will be shaping and changing our lives over the next ten years and beyond, including the market's response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the high potency APIs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The High Potency APIs market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider high potency APIs market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market
  • The market size section gives the market size ($b) covering both the historic growth of the market, the impact of the COVID-19 virus and forecasting its recovery
  • Market segmentations break down market into sub markets
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the impact and recovery trajectory of COVID-19 for all regions, key developed countries and major emerging markets
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
  • The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this
  • The high potency APIs market section of the report gives context. It compares the high potency APIs market with other segments of the high potency APIs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, high potency APIs indicators comparison

Scope


Markets Covered:


1) By Type: Innovative HPAPI; Generic HPAPI 2) By Synthesis Type: Synthetic HPAPI; Biotech HPAPI 3) By Therapeutic Application: Oncology; Hormonal Disorder; Glaucoma; Other Therapeutic Applications (Respiratory Disorders, CVD, Diabetes, Cosmetology, and Erectile Dysfunction)

Companies Mentioned: Eli Lily and Company; Novartis AG; Bristol-Myers Squibb Company; Roche Diagnostics Ltd; Sanofi

Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Table of Contents

1. Executive Summary2. HP (High Potency) APIs Market Characteristics3. HP (High Potency) APIs Market Trends And Strategies4. Impact Of COVID-19 On HP (High Potency) APIs
5. HP (High Potency) APIs Market Size And Growth
5.1. Global HP (High Potency) APIs Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global HP (High Potency) APIs Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. HP (High Potency) APIs Market Segmentation
6.1. Global HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Innovative HPAPI
  • Generic HPAPI
6.2. Global HP (High Potency) APIs Market, Segmentation By Synthesis Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Synthetic HPAPI
  • Biotech HPAPI
6.3. Global HP (High Potency) APIs Market, Segmentation By Therapeutic Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Oncology
  • Hormonal Disorder
  • Glaucoma
  • Other Therapeutic Applications (Respiratory Disorders, CVD, Diabetes, Cosmetology, and Erectile Dysfunction)

7. HP (High Potency) APIs Market Regional And Country Analysis
7.1. Global HP (High Potency) APIs Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global HP (High Potency) APIs Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific HP (High Potency) APIs Market
8.1. Asia-Pacific HP (High Potency) APIs Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China HP (High Potency) APIs Market
9.1. China HP (High Potency) APIs Market Overview
9.2. China HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India HP (High Potency) APIs Market
10.1. India HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan HP (High Potency) APIs Market
11.1. Japan HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia HP (High Potency) APIs Market
12.1. Australia HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia HP (High Potency) APIs Market
13.1. Indonesia HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea HP (High Potency) APIs Market
14.1. South Korea HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe HP (High Potency) APIs Market
15.1. Western Europe HP (High Potency) APIs Market Overview
15.2. Western Europe HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK HP (High Potency) APIs Market
16.1. UK HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany HP (High Potency) APIs Market
17.1. Germany HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France HP (High Potency) APIs Market
18.3. France HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe HP (High Potency) APIs Market
19.1. Eastern Europe HP (High Potency) APIs Market Overview
19.2. Eastern Europe HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia HP (High Potency) APIs Market
20.1. Russia HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America HP (High Potency) APIs Market
21.1. North America HP (High Potency) APIs Market Overview
21.2. North America HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA HP (High Potency) APIs Market
22.1. USA HP (High Potency) APIs Market Overview
22.2. USA HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America HP (High Potency) APIs Market
23.1. South America HP (High Potency) APIs Market Overview
23.2. South America HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil HP (High Potency) APIs Market
24.1. Brazil HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East HP (High Potency) APIs Market
25.1. Middle East HP (High Potency) APIs Market Overview
25.2. Middle East HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa HP (High Potency) APIs Market
26.1. Africa HP (High Potency) APIs Market Overview
26.2. Africa HP (High Potency) APIs Market, Segmentation By Type, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. HP (High Potency) APIs Market Competitive Landscape And Company Profiles
27.1. HP (High Potency) APIs Market Competitive Landscape
27.2. HP (High Potency) APIs Market Company Profiles
27.2.1. Eli Lily and Company
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Novartis AG
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Bristol-Myers Squibb Company
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Roche Diagnostics Ltd.
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Sanofi
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. HP (High Potency) APIs Pipeline Analysis29. Key Mergers And Acquisitions In The HP (High Potency) APIs Market30. HP (High Potency) APIs Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the high potency APIs (HPAPI) market are Eli Lily and Company, Novartis AG, Bristol-Myers Squibb Company, Roche Diagnostics Ltd., Sanofi, Hospira Inc., BASF SE, Covidien plc., Boehringer Ingelheim GmbH, Merck & Co. Inc., Sigma Aldrich Corporation, Bayer AG, Carbogen Amcis AG, Lonza, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Mylan Inc. , AbbVie, AstraZeneca plc. and GlaxoSmithKline PLC.

The global HP (High Potency) APIss market is expected to grow from $22.61 billion in 2021 to $24.53 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $34.04 billion in 2026 at a CAGR of 8.5%.

The high potency APIs (HPAPI) market consists of sales of high potency active pharmaceutical ingredients and related services. High potency APIs are extremely effective in pharmacologically active ingredients. These are highly specific in their action and offer significant efficiency even at the low daily therapeutic doses. HPAPIs are used in formulations for high potent drugs, owing to their ability to target precise disease cells including cancer cells.

The main types of HP (High Potency) APIs are innovative HPAPI and generic HPAPI. The various types of synthesis include synthetic HPAPI and biotech HPAPI that are used for therapeutic application such as oncology, hormonal disorder, glaucoma and other therapeutic applications (respiratory disorders, CVD, diabetes, cosmetology and erectile dysfunction). Glaucoma is a group of eye diseases that affect the optic nerve, which is essential for good vision.

North America was the largest region in the high potency APIs (HPAPI) market in 2021. Middle East is expected to be the largest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The rising number of cancer cases coupled with increasing sales of cancer drugs contributed to the growth of the high potency APIs market. Rising incidence of cancer is resulting in increasing R&D about anticancer drugs which in turn is propelling the demand for high potency APIs market. According to the World Health Organization’s International Agency for Research on Cancer (IARC) report, the cancer burden is expected to increase 29.5 million new cases and 16.4 million deaths by 2040, globally. Moreover, 70% of deaths from cancer occur in middle and low-income countries. Therefore, the growing incidence of cancer cases is projected to upsurge revenues for the high potency APIs market.

High investment requirements are anticipated to restrain the growth of the market over the coming years. The high potency APIs are cytotoxic, which are harmful to human cells. Moreover, they carry significant handling challenges including the requirement for specialized equipment to avoid cross-contamination, product protection, and to ensure environment and operator safety. Additionally, the requirement for appropriate process design and the constant evolution of technologies and industry standards, specialized containment facilities to facilitate the safety of the employees requires huge financial support. Therefore, large investment requirement acts as a major challenge for the growth of the high potency APIs market.

The companies dealing in the high potency APIs market are focusing on strategies such as production facility expansion and mergers & acquisitions to maintain their position in the competitive business environment. For instance, in June 2019, a Swiss-based chemicals and biotechnology company Lonza declared an investment in the expansion of HPAPI capability at its location in Visp, Switzerland, by connecting additional 4-m3-scale and multi-purpose manufacturing lines. The expansion enhances the current manufacturing ability of the business from the laboratory to the broad commercial level and further includes the resulting utilization of capacity in existing manufacturing facilities. In January 2020, Piramal Pharma Solutions (PPS) declared an expenditure of $19 million to enhance its operation in Aurora, Ontario, Canada, with an additional 975 m2 of production space in a new wing for API production, including the production of HPAPI for potent compounds down to an OEL of 1 mcg/m3.

In August 2019, Permira Funds, a U. K based global investment firm, acquired Cambrex Corporation for USD 2.4 million. Through this acquisition Permira Funds will provide financial support to Cambrex Corporation for its expansion of product manufacturing and analytical testing services. Cambrex Corporation is a life sciences company that offers products and services for small molecule active pharmaceutical ingredients with its headquarters in USA.

The countries covered in the high potency APIs (HPAPI) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Eli Lily and Company
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Roche Diagnostics Ltd.
  • Sanofi
  • Hospira inc.
  • BASF SE
  • Covidien plc.
  • Boehringer Ingelheim GmbH
  • Merck & Co. inc.
  • Sigma Aldrich Corporation
  • Bayer AG
  • Carbogen Amcis AG
  • Lonza
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer inc.
  • Mylan inc.
  • AbbVie
  • AstraZeneca plc.
  • GlaxoSmithKline plc.

Methodology

Loading
LOADING...